|
|
|
|
|
Legal status
Patent in force
| (51) | INT.CL. | C07D 487/04 | (2006.01) |
| A61K 31/495 | (2006.01) | ||
| A61P 25/00 | (2006.01) | ||
| A61P 29/00 | (2006.01) |
| (11) | Number of the document | 2552920 |
| (13) | Kind of document | T |
| (96) | European patent application number | 11711922.2 |
| Date of filing the European patent application | 2011-04-04 | |
| (97) | Date of publication of the European application | 2013-02-06 |
| (45) | Date of publication and mention of the grant of the patent | 2017-03-15 |
| (46) | Date of publication of the claims translation | 2017-06-12 |
| (86) | Number | PCT/EP2011/055218 |
| Date | 2011-04-04 |
| (87) | Number | WO 2011/121137 |
| Date | 2011-10-06 |
| (30) | Number | Date | Country code |
| 379028 P | 2010-09-01 | US | |
| 10305343 | 2010-04-02 | EP |
| (72) |
HOVEYDA, Hamid, BE
ROY, Marie-Odile, FR
FRASER, Graeme Lovat, BE
DUTHEUIL, Guillaume, BE
|
| (73) |
OGEDA SA,
Rue Adrienne Bolland 47, 6041 Charleroi,
BE
|
| (74) |
Liucija JANICKAITĖ,
Inpatra UAB, Šeškinės g. 59-53, LT-07162 Vilnius,
LT
|
| (54) | Nauji NK-3 receptoriaus selektyvūs antagonistų junginiai, farmacinė kompozicija ir būdai, skirti naudoti NK-3 receptoriaus sąlygotų sutrikimų gydymui |
| NOVEL NK-3 RECEPTOR SELECTIVE ANTAGONIST COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN NK-3 RECEPTORS MEDIATED DISORDERS |
| Payment date | Validity (years) | Amount | |
| 2025-03-18 | 15 | 289.00 EUR |
| 2026-04-04 |